4//SEC Filing
Aslan Fred 4
Accession 0001193125-25-285004
CIK 0001817241other
Filed
Nov 16, 7:00 PM ET
Accepted
Nov 17, 8:37 PM ET
Size
6.7 KB
Accession
0001193125-25-285004
Insider Transaction Report
Form 4
Aslan Fred
DirectorPresident and CEO
Transactions
- Tax Payment
Common Stock
2025-11-15$3.25/sh−6,347$20,628→ 350,374 total - Sale
Common Stock
2025-11-17$3.38/sh−6,375$21,522→ 343,999 total
Footnotes (3)
- [F1]Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
- [F2]The reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024.
- [F3]The weighted average sale price for the transaction reported was $3.376, and the range of prices were between $3.19 and $3.53. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Documents
Issuer
Artiva Biotherapeutics, Inc.
CIK 0001817241
Entity typeother
Related Parties
1- filerCIK 0001909362
Filing Metadata
- Form type
- 4
- Filed
- Nov 16, 7:00 PM ET
- Accepted
- Nov 17, 8:37 PM ET
- Size
- 6.7 KB